An observational study in Hepatic Cirrhosis With Variceal Bleeding and Cirrhotic Variceal Bleeding, sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 215 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.
Among the 215 studies in Liver Cirrhosis with a site in China, this one is the 33rd largest by enrollment of the 87 observational ones that give a count, is one of 20 that started in 2025, is one of 87 observational ones, and was the 215th registered.
1,302 studies on the registry are indexed under Liver Cirrhosis; 340 are open to participants now.
Browse Liver Cirrhosis studies →65 of the 215 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:
Fifth Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 18+
Air Force Military Medical University, China · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18–80
The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital · Sites in China
Ages 30–80
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 207 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 65 (31%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
215 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 25 · Phase 3 12 · Phase 4 22
First in 2005; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 614 is above the median of 171 across 527 observational studies indexed under Liver Cirrhosis.
Median enrollment 120 across the 127 interventional studies, 447 across the 87 observational. Of the 61 that completed or were terminated, 6 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 215 have an industry lead sponsor. The 10 most frequent:
Third Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 134 studies on the registry; 35 are open to participants now.
Third Affiliated Hospital, Sun Yat-Sen University has 9 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
14 of the studies in Liver Cirrhosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06779058Shengjing HospitalMR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B | 2026-12-01 |
| NCT06770283Second Affiliated Hospital, School of Medicine, Zhejiang UniversitySpirulina Tablets Treat Liver Fibrosis/Cirrhosis | 2026-12-26 |
| NCT07252102Zhejiang UniversityEffect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients | 2026-12-28 |
| NCT05974904Chongqing Medical UniversityAssociation of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study | 2026-12-28 |
| NCT06762223Xiqiao ZhouHenagliflozin on Liver Fibrosis in Patients with MASLD and T2DM | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 215 studies in Liver Cirrhosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multi-center bidirectional cohort study. The aim is to investigate the potential circadian rhythm of the bleeding pattern of gastric esophageal varices rupture in liver cirrhosis, as well as other related mechanisms and external influencing factors related to the timing. This will help to better prevent the occurrence or aggravation of the disease and provide more effective timing-based treatment and prevention strategies for patients.
1.1 Research Background and Objectives: All systems and organs exhibit pathological physiological changes related to circadian rhythms, and thus circadian rhythms are closely associated with the occurrence and development of many diseases. The study of the circadian rhythm of gastric esophageal variceal bleeding in liver cirrhosis involves the first study in 1993 that included 744 cases of bleeding events, which found that the onset time of variceal bleeding (608 cases) in alcoholic liver cirrhosis (279 cases) and non-alcoholic liver cirrhosis (329 cases) showed significant circadian rhythm (P\<0.05), with two peaks occurring at 08:00 and 20:00 respectively. A study in 1996 that included 212 cases of bleeding events also confirmed the circadian rhythm of the bleeding time in patients with liver cirrhosis.
Exploring the potential circadian rhythm of the circadian rhythm of gastric esophageal variceal bleeding in liver cirrhosis, other related mechanisms, and external influencing factors related to the timing, is helpful for better prevention of the occurrence or aggravation of the disease and providing more effective treatment and prevention strategies based on timing for patients.
1.2 Design Type: Prospective, multicenter cross-sectional study 1.3 Study Subjects Inclusion criteria
(1) Non-variceal bleeding found by gastroscopy (2) Severe extraliver diseases, heart, lung, kidney, brain dysfunction, excluding liver cirrhosis-induced hepatic encephalopathy, liver-kidney syndrome, liver-pulmonary syndrome (3) Complicated with malignant tumors other than primary liver cancer 1.4 Sample size This study is a cross-sectional study, investigating the time rhythm of variceal bleeding. According to the 2009 study on the time rhythm of variceal bleeding [3], it is divided into 12 time periods. The bleeding rate in the high-incidence period is 20.83%, the expected effect size is 12.5%, the confidence level 1-α = 0.95, and the statistical power 1-β = 0.8. The sample size N = 201 was calculated using PASS 16.0 software. An additional 15% sample size was added using the cosine model, considering a 10% non-response rate, then the required sample size N = 257 cases. The number of cases in this center / total cases = 1/2.
1.5 Observation indicators Demographic information: Name, gender, age, patient ID General condition: Weight, height Medical history: Cause of liver cirrhosis, bleeding method, bleeding date, bleeding time, admission date, admission time, gastroscopy date, gastroscopy time, whether combined with primary liver cancer, whether having chronic diseases, whether using NSBB and anticoagulant platelet inhibitors, whether combined with ascites or hepatic encephalopathy Laboratory tests: Blood routine, blood biochemistry, coagulation; Imaging data: Results of liver and spleen color Doppler ultrasound, spleen length diameter, liver elasticity 1.6 Statistical analysis methods The Cosinor rhythm model was used to perform sinusoidal fitting of the bleeding time, and the changes in 24-hour bleeding rhythm were fitted; qualitative and quantitative differences between subgroups were tested using chi-square test or Fisher's exact test for categorical variables, and Student's t-test or Mann-Whitney U test for continuous variables. Paired t-test or analysis of variance was used to compare the differences in MELD score and Child-Pugh score between time points. Multivariate logistic regression analysis was used to estimate odds ratios (ORs) and their 95% confidence intervals. All statistical tests were two-sided tests. p \< 0.05 was considered statistically significant.
Patients aged 18 years or older with clinically diagnosed liver cirrhosis presenting with variceal bleeding manifested as hematemesis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclusion Criteria 1. Aged 18 years or above 2. Clinically diagnosed with liver cirrhosis 3. Presenting with overt acute upper gastrointestinal bleeding, specifically hematemesis 4. Informed consent obtained Exclusion Criteria (1) Non-variceal bleeding identified on gastroscopy (2) Severe extrahepatic diseases, including cardiopulmonary, renal, or cerebral insufficiency, excluding hepatic encephalopathy, hepatorenal syndrome, and hepatopulmonary syndrome secondary to liver cirrhosis (3) Concurrent malignancy other than primary liver cancer (4) Pregnant or breastfeeding women
variceal bleeding
Acute Variceal Upper Gastrointestinal Bleeding in Liver Cirrhosis Presenting as Hematemesis;After admission, the time of first onset of this bleeding episode was recorded following confirmation via gastroscopic exploration.
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Oct 2026, 15 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Third Affiliated Hospital, Sun Yat-Sen University →